| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
866,303 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
55,541 |
496,602 |
| Total Sell Value |
$0 |
$0 |
$11,412,520 |
$89,768,813 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
19 |
72 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siegall Clay B |
President and CEO |
• • – |
2020-03-09 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
758,984 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-03-06 |
4 |
AS |
$114.53 |
$919,292 |
D/D |
(8,000) |
188,674 |
|
50% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-03-06 |
4 |
OE |
$12.00 |
$108,117 |
D/D |
8,000 |
193,172 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-02-18 |
4 |
AS |
$116.33 |
$40,716 |
D/D |
(350) |
107,659 |
|
38% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-02-10 |
4 |
AS |
$113.39 |
$3,263,110 |
D/D |
(28,472) |
758,784 |
|
45% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-02-10 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
767,070 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-02-03 |
4 |
AS |
$108.51 |
$78,887 |
D/D |
(727) |
108,009 |
|
39% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-01-08 |
4 |
AS |
$111.28 |
$3,169,433 |
D/D |
(28,472) |
758,784 |
|
42% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-01-08 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
785,937 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2020-01-07 |
4 |
OE |
$12.76 |
$223,300 |
D/D |
17,500 |
90,263 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
871 |
158,438 |
|
- |
|
| Taylor Robin G |
Chief Commercial Officer |
• – – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
61 |
33,025 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Afairs |
• – – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
697 |
71,385 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,465 |
108,611 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
871 |
188,389 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2019-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
758,784 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2019-12-16 |
4 |
AS |
$114.07 |
$228,140 |
D/D |
(2,000) |
101,146 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2019-12-09 |
4 |
AS |
$114.08 |
$3,261,641 |
D/D |
(28,472) |
755,684 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2019-12-09 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
756,184 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2019-12-06 |
4 |
AS |
$117.09 |
$937,265 |
D/D |
(8,000) |
187,518 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2019-12-06 |
4 |
OE |
$12.00 |
$96,000 |
D/D |
8,000 |
195,518 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2019-11-25 |
4 |
S |
$121.48 |
$607,388 |
D/D |
(5,000) |
103,146 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2019-11-25 |
4 |
OE |
$65.11 |
$325,550 |
D/D |
5,000 |
108,146 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2019-11-21 |
4 |
S |
$119.51 |
$2,096,120 |
D/D |
(17,500) |
40,168 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2019-11-21 |
4 |
OE |
$19.02 |
$332,850 |
D/D |
17,500 |
45,110 |
|
- |
|
1805 Records found
|
|
Page 18 of 73 |
|
|
